Poolbeg Pharma - Update

Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza.

Cathal Friel
Jeremy Skillington
Chief Executive Officer

Company Events - POOLBEG PHARMA